Neurology therapeutics Market | Neurology Devices Market
Medical Devices Market Blooms as the Key MedTech Companies Continue to Bring-In Innovation
parkinson's
Parkinson’s and tuberculosis sh...

A group of researchers has recently discovered that an immune mechanism responsible in clearing bacterial i...

Entasis
Business Cocktail

Zymeworks Daiichi I-O deal could potentially be worth USD 485 million Zymeworks and Daiichi Sankyo teamed u...

takeda
Takeda buys Shire in a deal worth USD...

Japan's largest drugmaker Takeda has successfully closed a deal worth USD 62 billion to buy another pharma ...

transthyretin amyloidosis
Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set...

Atara Biotherapeutics hires ex-Genentech SVP to lead its global R&D program Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&D global head. During the time in Gene...


Default Blog Image
Horizon Discovery declines Abcam’s USD 367 million takeover bid

Horizon Discovery declines Abcam’s USD 367 million takeover bid Horizon Discovery has recently rejected a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing...


Chronic inflammatory demyelinating polyneuropathy therapies are required with novel and targeted mechanism of action that are more effective, specific, cost effective, and less toxic than existing available treatments.
Chronic Inflammatory Demyelinating Polyneuropathy – lack of Effective treatment

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder which is described as the inflammation of nerve roots and peripheral nerves and destruction of the fatty pro...


Default Blog Image
Hepatic Encephalopathy- Lack of active pipeline products

Hepatic encephalopathy (HE) can be described as deterioration of brain function occurring due to accumulation of toxic substances in the blood which ultimately reach the brain. People with long-st...


takeda
Takeda acquisition on Shire raises its share by 25 percent

Takeda revealed on Wednesday that it is thinking to obtain Shire, which led to rise in its share by 25 percent. It also revealed that there has been no approach made to Shire's board and the propos...


BioGen
Business Cocktail

Novo Holdings optimistic about investments in life sciences Novo Holdings is planning to increase its investment in early & late stage biotechs. Its focus will be mainly in the U.S. and Europe...


Cocaine Use Disorder Market
Cocaine Use Disorder...

Cocaine Use Disorder (CUD) is characterized as a substance use disorder in which biological, psychol.....

Cardiovascular Disease Devices Whitepaper
Cardiovascular Disease De...

Today, the sedentary lifestyle adopted among people has led to cause a myriad of underlying diseases.....

Lupus Nephritis Market
Lupus Nephritis...

Lupus Nephritis (LN) is one of the most common manifestations of systemic lupus erythematosus (SLE),.....

Editor's Pick
Bone Metastasis Market: A Debilitating Consequence for Many Tumors

In advanced cancer patients, the most common site for the occurrence of metastasis is c...

Evaluating the Role of Digital Therapeutics as an Alternative to Conventional...

Depression is a mental condition characterized by prolonged series of poor moods, loss ...

Exploring the Market Potential of the Upcoming Therapies for the Myasthenia G...

Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It ...

Scrutinizing the West Syndrome Market Space from Growth Perspectives

West syndrome is a rare form of neurological disorder, an age-related specific Epilepti...

Recent Inclination of Pharma Companies, Emerging Pipeline Therapies Drive the...

Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. ...